Pretreatment testing |
|
|
|
Protocol for augmentation therapy¶ |
- Product: Pooled plasma-derived alpha-1-antiprotease (Aralast NP, Prolastin-C, Zemaira, and Glassia).
|
|
- Patient's weight: ____kg.
|
- Calculate patient's dose: 60 mg × weight in kg = _____weekly dose.
|
- Aralast NP, Prolastin-C, and Zemaira are supplied as lyophilized preparations and require reconstitution according to the package insert. After reconstitution, pooled AAT should be used within three hours.
|
- Infusion rate depends on specific products used and ranges from ≤0.2 mL/kg/minute to 0.08 mL/kg/minute. Consult package insert. The rate can be adjusted, if needed for patient comfort.
|
Supportive care |
- Cessation of smoking and avoidance of passive smoke exposure.
|
- Avoidance of respiratory irritants.
|
- Pulmonary rehabilitation if reduced exercise capacity.
|
- Oxygen therapy (as needed).
|
- Nutritional support as appropriate to maintain healthy body weight.
|
- Influenza and pneumococcal vaccinations.
|
- Treatment of respiratory infections (eg, influenza, bacterial bronchitis, flares of bronchiectasis, pneumonia).
|
- Inhaled bronchodilators and glucocorticoids per guidelines for COPD.
|
- Vaccination against hepatitis A and B viruses, if not already immune.◊
|